FDA 483 - KP Pharmaceutical Technology - February 03, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of KF Pharmaceutical Technology in Bloomington, IN, revealed significant deficiencies in quality assurance procedures and equipment suitability. The firm failed to adequately manage visual inspection processes, environmental controls, and their water system, indicating potential risks to product quality and purity. These issues include lack of AQL testing, unqualified visual inspectors, inadequate particulate control, and insufficient documentation and testing of the water system.
ID · af93ffc6-90c2-4cba-8eba-f8fa21b7a395